| Literature DB >> 30671173 |
Érica Martins de Lavor1, Antônio Wilton Cavalcante Fernandes1, Roxana Braga de Andrade Teles1, Ana Ediléia Barbosa Pereira Leal1, Raimundo Gonçalves de Oliveira Júnior2, Mariana Gama E Silva1, Ana Paula de Oliveira1, Juliane Cabral Silva1, Maria Tais de Moura Fontes Araújo1, Henrique Douglas Melo Coutinho3, Irwin Rose Alencar de Menezes3, Laurent Picot2, Jackson Roberto Guedes da Silva Almeida1.
Abstract
Inflammatory diseases result from the body's response to tissue damage, and if the resolution is not adequate or the stimulus persists, there will be progression from acute inflammation to chronic inflammation, leading to the development of cancer and neurodegenerative and autoimmune diseases. Due to the complexity of events that occur in inflammation associated with the adverse effects of drugs used in clinical practice, it is necessary to search for new biologically active compounds with anti-inflammatory activity. Among natural products, essential oils (EOs) present promising results in preclinical studies, with action in the main mechanisms involved in the pathology of inflammation. The present systematic review summarizes the pharmacological effects of EOs and their compounds in in vitro and in vivo models for inflammation. The research was conducted in the following databases: PubMed, Scopus, BIREME, Scielo, Open Grey, and Science Direct. Based on the inclusion criteria, 30 articles were selected and discussed in this review. The studies listed revealed a potential activity of EOs and their compounds for the treatment of inflammatory diseases, especially in chronic inflammatory conditions, with the main mechanism involving reduction of reactive oxygen and nitrogen species associated with an elevation of antioxidant enzymes as well as the reduction of the nuclear factor kappa B (NF-κB), reducing the expression of proinflammatory cytokines. Thus, this review suggests that EOs and their major compounds are promising tools for the treatment of chronic inflammation.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30671173 PMCID: PMC6323437 DOI: 10.1155/2018/6468593
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Flowchart detailing literature searching and screening.
General characteristics of included studies (in vitro and in vivo reports).
| Authors, year, country | Model | Essential oil | Major constituents | Family | Induction of inflammation | Type of inflammation |
|---|---|---|---|---|---|---|
| Tsai et al., 2011, Taiwan [ | Essential oils of the aerial parts of | 1,8-Cineole | Myrtaceae | Lipopolysaccharide (LPS) from | Inflammation induced by biological agent | |
| Ritter et al., 2013, Brazil [ | — | Anethole | — | Complete Freund's adjuvant | Inflammation induced by biological agent | |
| Jeena et al., 2013, India [ | Essential oil of ginger | Zingiberene | Zingiberaceae | Formalin | Inflammation induced by chemical agent | |
| El-Readi et al., 2013, Egypt [ | Essential oils from leaves and stems of | Altingiaceae | LPS from | Inflammation induced by biological agent | ||
| Valente et al. 2013, Portugal [ | Essential oils of the aerial parts of | Apiaceae | LPS from | Inflammation induced by biological agent | ||
| Lin et al., 2014, China [ | Essential oil of | Caryophyllene oxide | Caprifoliaceae | LPS from | Inflammation induced by biological agent | |
| Destryana et al., 2014, Indonesia [ | Essential oil from leaf and branches of | Lauraceae | LPS from | Inflammation induced by biological agent | ||
| Shirole et al., 2014, India [ | Essential oil of | 4-Carvomenthenol | Anacardiaceae | LPS from | Inflammation induced by biological agent | |
| Patil et al. 2014, India [ | Essential oil of | — | Theaceae | Indomethacin | Inflammation induced by chemical agent | |
| Khodabakhsh et al. 2014, Japan [ | Essential oil from blossoms of | Linalool | Rutaceae | Cotton pellet—subcutaneous | Inflammation induced by physical agent | |
| Wu et al., 2014, China [ | — | Linalool | — | Inflammation induced by biological agent | ||
| Jeena et al., 2014, India [ | Essential oil of | Caryophyllene | Piperaceae | Formalin | Inflammation induced by chemical agent | |
| Entok et al., 2014, Turkey [ | Essential oil of | — | Ranunculaceae | LPS from | Inflammation induced by biological agent | |
| Kazemi 2015, Iran [ | Essential oils | Thymol | Asteraceae | LPS from | Inflammation induced by biological agent | |
| Pinheiro et al., 2015, Brazil [ | Essential oil from leaves of | — | Rutaceae | Dorsal subcutaneous injection of sterile air and carrageenan suspension | Inflammation induced by chemical agent | |
| Kara et al. 2015, Turkey [ | — | Carvacrol | — | LPS from | Inflammation induced by biological agent | |
| Allam et al. 2015, Egypt [ | Essential oil of thyme | — | Lamiaceae | Inflammation induced by biological agent | ||
| Shen et al. 2016, China [ | Essential oil of calyx of | Malvaceae | LPS from | Inflammation induced by biological agent | ||
| Park et al., 2016, Korea [ | Essential oil of | — | Cupressaceae | Inflammation induced by biological and chemical agent | ||
| Skala et al., 2016, Poland [ | Essential oils from roots of | Cyperene | Asteraceae | LPS from | Inflammation induced by biological agent | |
| Zhao et al., 2016, China [ | — | Cinnamaldehyde | — | LPS from | Inflammation induced by biological agent | |
| Yu et al., 2016, Brazil [ | — | Thymol | — | High-fat-diet-induced hyperlipidemia and atherosclerosis. | Inflammation induced by chemical agent | |
| Kennedy-Feitosa et al. 2016, Brazil [ | — | Eucalyptol | — | Exposition to commercial cigarettes | Inflammation induced by chemical agent | |
| Alvarenga et al. 2016, Brazil [ | — | Carvacrol | — | Irinotecan | Inflammation induced by chemical agent | |
| Shen et al., 2017, China [ | Essential oil from blossoms of | — | Rutaceae | LPS from | Inflammation induced by biological agent | |
| Liu et al., 2017, China [ | — | — | High-fat-diet-induced hyperlipidemia and atherosclerosis | Inflammation induced by chemical agent | ||
| Leelarungrayub et al. 2017, Thailand [ | Essential oil of | Terpinen-4-ol | Zingiberaceae | LPS from | Inflammation induced by biological agent | |
| Arigesavan and Sudhandiran 2017, India [ | — | Carvacrol | — | 1,2-Dimethylhydrazine (DMH) and dextran sodium sulphate (DSS) | Inflammation induced by chemical agent | |
| Marques et al., 2018, Brazil [ | — | l-Carveol, l-carvone, | — | LPS from | Inflammation induced by biological agent | |
| Pivetta et al. 2018, Brazil [ | — | Thymol in nanoparticles from natural lipids | — | Imiquimod | Inflammation induced by chemical agent | |
Figure 2Distribution of the selected studies by country (a) and year of publication (b).
In vitro studies involving essential oils, anti-inflammatory and antioxidant activity.
| Essential oil and/or majority constituent | Doses | Antioxidant and anti-inflammatory assays | Cell line | General results and proposed mechanism of action | Reference |
|---|---|---|---|---|---|
| Essential oils of the aerial part of | 0.01 | THP-1 (human mylomonocytic cell) | Strong antioxidant activity in the tests performed; inhibition of 5-LOX activity and reduction of IL-1 | Tsai et al. 2011 [ | |
| Essential oils of the aerial parts of | EO: 0.08, 0.16, and 0.32 | Measurement of NO, Western blot analysis for iNOS, and nitric oxide scavenging activity | RAW 264.7 macrophages | Strong NO scavenging activity and inhibition of iNOS expression | Valente et al. 2013 [ |
| Essential oils from leaves and stems of | 1, 10, 100 and 500 | 5-LOX and PGE2 inhibition | HepG-2 cells | Reduction of DPPH, (OH•), and (O2•) radicals | El-Readi et al. 2013 [ |
| Essential oil of | 50, 100, 150, 200, and 250 | Measurement of IL-1 and IL-6 | BV-2 cell (microglia) | Inhibition of the production of IL-1 and IL-6; scavenging activity against the DPPH radical | Jing et al. 2014 [ |
| Essential oil from leaf and branches of | 5, 10, an 20 | RAW 264.7 macrophages | The EO of | Destryana et al. 2014 [ | |
| Essential oils | DPPH radical scavenging and FRAP assay | RAW 264.7 macrophages | Kazemi 2015, Iran [ | ||
| Essential oil of calyx of | 25, 50, 100, 200, and 300 | Determination of NO production | RAW 264.7 macrophages | Inhibition of NF- | Shen et al. 2016 [ |
| Essential oil of | RAW 264.7 macrophages | Decreasing in the number of total cells and suppression of TNF- | Park et al. 2016 [ | ||
| Essential oils from roots of | 25, 50, and 100 | Measurement of cytokines IL-1 | Human astrocytes | Decreasing the expression of IL-1 | Skala et al. 2016 [ |
| Essential oil from blossoms of | 15.625, 31.25, 62.5, 125, and 250 | DPPH and ABTS radical scavenging activity | RAW 264.7 macrophages | Did not show scavenging effects on DPPH and ABTS radicals | Shen et al. 2017 [ |
| l-Carveol, l-carvone, | 1, 10, and 100 | Protective effect against oxidative damage produced by superoxide anion production (O2·−) and hydrogen peroxide | RAW 264.7 macrophages | Reduction in TNF- | Marques et al. 2018 [ |
EO: essential oil; NO: nitric oxide; ROS: reactive oxygen species; iNOS: inducible nitric oxide synthase; IL-1β: interleukin-1 beta; DPPH: 2,2-diphenyl-1-picrylhydrazyl radical; LPS: lipopolysaccharide; M: male; ABTS: 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid); NF-κB: nuclear factor kappa B, COX-2: cyclooxygenase; TNF-α: tumor necrosis factor alpha; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; FRAP: ferric reducing antioxidant power; MPO: myeloperoxidase; PCR-RT: real-time quantitative polymerase chain reaction; H2DCF-DA: 2′,7′-dichlorodihydrofluorescein diacetate; 5-LOX: 5, lipoxygenase; PGE2: prostaglandin E2; MAPK: mitogen-activated protein kinases; GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
In vivo studies involving essential oils and antioxidant activity.
| Essential oil and/or majority constituent | Animals (strain/sex), | Doses, route, and administration period | Antioxidant assays | Experimental model of inflammation | General results | Reference |
|---|---|---|---|---|---|---|
| Essential oil of ginger | Mice (Balb/c/), | 10, 50, 100, 250, 500, or 1000 mg/kg (i.p. or p.o.), single dose or 4 days | Lipid peroxidation, SOD and hydroxyl activity assay | Formalin induced chronic inflammation | Scavenged superoxide, DPPH, hydroxyl radicals, and lipid peroxidation inhibition | Jeena et al. 2013 [ |
| Anethole | Mice (Swiss/M), | 125, 250, or 500 mg/kg (p.o.), for until 7 days | MPO activity | Paw edema induced by complete Freund's adjuvant | Inhibition of paw edema on all of the days analyzed | Ritter et al. 2013 [ |
| Essential oil of | Rats (Sprague–Dawley), | 500 mg/kg (p.o.), 3 times a 1 day | Determination of SOD, CAT activity, and MDA and NO levels | LPS induced inflammation | Increase in SOD and CAT, and reduction of MDA and NO in lung | Entok et al. 2014 [ |
| Essential oil of | Mice (Balb/C), | 10, 50, 100, 250, 500, or 1000 mg/kg (i.p. or p.o.), 5 or 30 days. | Lipid peroxidation and SOD and hydroxyl activity assay | Formalin induced chronic inflammation | Scavenged SOD, DPPH, and hydroxyl radicals; inhibition of lipid peroxidation | Jeena et al., 2014 [ |
| Linalool | Mice (C57BL/6J/M), | 5, 15 or 25 mg/kg (s.c.) | ROS and SOD activity assay | Increase in nuclear Nrf-2 protein amount and reduction in SOD expression | Wu et al. 2014 [ | |
| Essential oil from blossoms of | Rats (Wistar/M), | 5, 10, 20, 40, or 80 mg/kg (i.p.) for until 7 days | Measurement of NO | Cotton pellet-induced granuloma | Decrease in transudate and granuloma formation amount involving the nitric oxide pathway | Khodabakhsh et al. 2014 [ |
| Essential oil of | Rats (Wistar/M), | 200 or 400 mg/kg (p.o.) for 11 days | Colonic GSH content and lipid peroxides concentration | Enterocolitis induced by indomethacin | Decrease in macroscopic and microscopic scores for inflammation | Patil et al., 2014 [ |
| Essential oil of | Rats (Sprague-Dawley/F), | 5-30 | DPPH radical scavenging, lipoxygenase activity, and measurement of NO and MPO | LPS- and ovalbumin-induced bronchial inflammation | Inhibition of lipoxygenase enzyme and DPPH scavenging activity | Shirole et al. 2014 [ |
| Essential oil of thyme | Rats (Sprague-Dawley/M), | 7, 5, 15, or 30 mg/kg (i.p.) for 21 days | FRAP assay | Ulcer-forming induced by | Synergistic activity of thyme oil decreased the inflammation of the lamina propria and decreased the bacterial load in the colon | Allam et al. 2015 [ |
| Essential oil from leaves of | Mice (Webster/M), | 3-10 or 30 mg/kg (p.o.) | NO levels and trapping capacity of anthranilates | Formalin test and subcutaneous air pouch (SAP) model | Reduction in migration, exudate volume, and protein extravasation and reduced levels of NO, TNF- | Lin et al. 2014 [ |
| Carvacrol | Rats (Sprague-Dawley/F), | 20, 40, or 80 mg/kg (p.o.) for 6 days | MDA and NO levels | LPS-induced peritoneal inflammation | Decrease in levels of TNF- | Kara et al., 2015 [ |
| Cinnamaldehyde | Rats (Sprague-Dawley/M), | 30, 60, or 90 (p.o.) 1x/day for 30 days | Determination of intracellular levels of ROS | LPS-induced cardiac dysfunction | Inhibition of cardiac dysfunction, inflammatory infiltration, and the levels of TNF- | Zhao et al., 2016 [ |
| Thymol | Rabbits (M), | 3 or 6 mg/kg (p.o) for 8 weeks | DPPH and ABTS radical scavenging activity and measurement of MDA level in serum | Inflammatory process in aortic intimal thickening | High antioxidant activity in both tests | Yu et al. 2016 [ |
| Eucalyptol | Mice (C57BL/6/M), | 1, 3, and 10 mg/mL via inhalation (15 min/daily) for 5 days | NBT assay, SOD and CAT activity | Cigarette smoke exposure | Reduction in IL-1 | Kennedy-Feitosa et al., 2016 [ |
| Carvacrol | Mice (Swiss/F), | 25, 75, or 150 mg/kg (i.p.) for 8 days | GSH, MDA, and NO levels | Intestinal mucositis induced by CPT-11 chemotherapy | Reduction in TNF- | Alvarenga et al. 2016 [ |
| Mice ApoE−/− (C57BL/6/M), | Not related | Measurement of eNOS and NO concentrations, ROS assay, enzyme activity SOD, CAT, GPx, GSH, and MDA | Atherosclerosis induced by high fat | Inhibition of atherosclerotic lesion size and increase in plaque stability | Liu et al. 2017 [ | |
| Carvacrol | Rat (Fischer 344/M), | 50 mg/kg (p.o.) for 7 days before and 7 days, after tumor induction | Antioxidant enzyme activities SOD, CAT, GPx, GR, GSH, vitamin E and vitamin C, and NO level and MDA contents | Colitis induced by DMH-associated colon cancer | Increase in SOD, CAT, and GSH levels and reduction in LPO, MPO, and NO | Arigesavan and Sudhandiran 2017 [ |
| Essential oil of | Rats (Wistar/M), | 12.5–400 | DPPH radical scavenging | LPS-induced subcutaneous inflammatory assay | Inhibition of DPPH radical and decrease in skin temperature and blood flow, reducing tissue inflammation process | Leelarungrayub et al. 2017 [ |
| Thymol in nanoparticles from natural lipids | Mice (C57B/6/M), | 5 mg/day (p.o.), 15 days | Anthralin-induced ear edema model | Imiquimod-induced psoriasis | Improved inflammation and healing, on anthralin model and imiquimod | Pivetta et al. 2018 [ |
eNOS: nitric oxide synthase; NO: nitric oxide; ROS: reactive oxygen species; SOD: superoxide dismutase; CAT: catalase; GPx: glutathione peroxidase; GSH: glutathione; GR: reductase glutathione; MDA: malondialdehyde; DMH: 1,2-dimethyl hydrazine; LPO: lipid peroxides; iNOS: inducible nitric oxide synthase; IL-1β: interleukin-1 beta; DPPH: 2,2-diphenyl-1-picrylhydrazyl radical; LPS: lipopolysaccharide; M: male; ABTS: 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid); TC: total cholesterol; TG: triglycerides; LDL: low-density lipoprotein; VCAM-1: vascular cell adhesion molecule-1; MCP-1: monocyte chemotactic protein-1 (MCP-1); NBT: nitroblue tetrazolium; TBARS: thiobarbituric acid; NF-κB: nuclear factor kappa B; MDA: malondialdehyde; CPT-11: irinotecan, Camptosar, Camptothecin-11; COX-2: cyclooxygenase; TNF-α: tumor necrosis factor alpha; IL-6: interleukin-6; IL-17: interleukin-17; FRAP: ferric reducing antioxidant power; MPO: myeloperoxidase; TNBS: trinitrobenzenesulphonic acid; Nrf-2: nuclear factor erythroid 2–related factor 2; PMA: phorbol-12-myristate-13-acetate.
Figure 3Methodological quality of included in vivo studies. White bars indicate the proportion of articles that met each criterion; black bars indicate the proportion of studies that did not, and gray bars indicate the proportion of studies with unclear answers.
Figure 4Chemical structure of the major constituents of the essential oils evaluated as antioxidant and anti-inflammatory in chronic inflammation.
Figure 5Chemical structure of the constituents isolated of the essential oils evaluated as antioxidant and anti-inflammatory in chronic inflammation.
Figure 6Molecular mechanisms of action of essential oils activity mediating signaling involving inhibition of NF-κB, MAPK, and decreased intracellular oxidative stress.